The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Abstract
Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose and recommended phase 2 dose of trametinib and to assess its safety, pharmacokinetics, pharmacodynamics, and response rate in individuals with advanced solid tumours. Methods We undertook a multicentre phase 1 study in patients with advanced solid tumours and adequate organ function. The study was in three parts: dose escalation to define the maximum tolerated dose; identification of the recommended phase 2 dose; and assessment of pharmacodynamic changes. Intermittent and continuous dosing regimens were analysed. Blood samples and tumour biopsy specimens were taken to assess pharmacokinetic and pharmacodynamic changes. Adverse events were defined with common toxicity criteria, and tumour response was measured by Response Evaluation Criteria In Solid Tumors. This study is registered with ClinicalTrials.gov, number NCT00687622. Findings We enrolled 206 patients (median age 58·5 years, range 19-92). Dose-limiting toxic effects included rash (n=2), diarrhoea (n=1), and central serous retinopathy (n=2). The most common treatment-related adverse events were rash or dermatitis acneiform (n=165; 80%) and diarrhoea (87; 42%), most of which were grade 1 and 2. The maximum tolerated dose was 3 mg once daily and the recommended phase 2 dose was 2 mg…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, direct inhibition of MAPK signaling has posed therapeutic challenges due to associated adverse effects 39,40 , including retinal toxicity, increased risk of retinal fibrosis, photoreceptor degeneration, and impaired retinal pigment epithelium (RPE) function, necessitating the development of alternative therapeutic strategies.”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [39]
In the citing paper
“However, the results of clinical trials with MEK inhibitor (MEKi) were disappointing in CRC patients [13, 14].”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [14]
Citations
Cites
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., Rominger, C. M., Erskine, S., Fisher, K. E., Yang, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2200 · Cited by 587
Adjei, A. A., Cohen, R. B., Franklin, W., Morris, C., Wilson, D., Molina, J. R., Hanson, L. J., Gore, L., Chow, L., Leong, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4956 · Cited by 570
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P., Moy, C., Szabo, S. A., Roadcap, L. T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 546
Self-citationCommon Terminology Criteria for Adverse Events v3.0 (CTCAE)
(2008) · Principles and Practice of Clinical Trial Medicine · doi:10.1016/b978-0-12-373695-6.00022-3 · Cited by 457
LoRusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.415 · Cited by 401
Cited by
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 696
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Dombi, E., Baldwin, A., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Whitcomb, P., Martin, S., Aschbacher-Smith, L. E., Rizvi, T. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605943 · Cited by 682
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Metadata
- Authors
- Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V. G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris, H. A., & Messersmith, W. A.
- Affiliations
- Sarah Cannon (US)
- Abramson Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Cancer Center (US)
- Pinnacle Oncology Hematology (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Infante, Jeffrey R
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 13
- Issue
- 8
- Pages
- 773-781
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2100738068
- Cited by
- 552
- References
- 23
- Citations by year
- 2026: 12 · 2025: 31 · 2024: 26 · 2023: 44 · 2022: 48 · 2021: 31 · 2020: 37 · 2019: 37 · 2018: 36 · 2017: 37 · 2016: 63 · 2015: 49 · 2014: 50 · 2013: 45 · 2012: 5
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- trametinib, MEK inhibitors, maximum tolerated dose, recommended phase 2 dose, dose-limiting toxicity, acneiform rash, diarrhea, central serous chorioretinopathy, pharmacokinetics, pharmacodynamics, pathway inhibition, advanced solid tumors, oral anticancer drugs, tumor response rate
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Biopsy, Drug Administration Schedule, Female, Half-Life, Humans, Male, Metabolic Clearance Rate, Middle Aged, Neoplasms, Pyridones, Pyrimidinones, United States, Treatment Outcome, Drug Monitoring, Area Under Curve, Maximum Tolerated Dose, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70270-x
- The paper
- Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., Peddareddigari, V. G., Le, N. T., Hart, L., Bendell, J. C., Eckhardt, G., Kurzrock, R., Flaherty, K., Burris, H. A., & Messersmith, W. A. (2012). Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70270-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.